Hospital & Healthcare Management May 15, 2024
Merck KGaA has inked a potential $1.4 billion deal with Texas-based Caris Life Sciences for the discovery and development of first-in-class antibody-drug conjugate candidates for cancer patients, the companies announced.
Under the multi-year partnership, Merck KGaA will provide an undisclosed upfront payment to Caris along with research funding. Merck KGaA will also be responsible for the preclinical and clinical research of the discovered targets and the eventual development and commercialization work.
Caris, an artificial intelligence and precision medicines company, will be eligible to receive discovery, development, regulatory and sales-based milestone payments totaling $1.4 billion and tiered royalties. In return, Merck KGaA secures the exclusive global license to develop, manufacture and eventually commercialize the antibody-drug conjugates (ADCs).
“This partnership adds to...
Today's Sponsors
Today's Sponsor